Omidenepag Isopropyl 0.002% Suppliers & Bulk Manufacturers

Available Forms: Eye Drops

Available Strengths: 0.002%

Reference Brands: Eybelis

Category: Opthalmology

Omidenepag isopropyl 0.002% eye drops lower eye pressure in glaucoma and ocular hypertension. It is a selective EP2 receptor agonist, a different mechanism from prostaglandin analogues such as latanoprost, and is used once daily. It was developed by Santen and is sold as Eybelis in Japan and Omlonti in the US. Patent status differs by country, so we confirm what can lawfully be supplied to your destination before quoting.

Product Description:

Omidenepag isopropyl ophthalmic solution 0.002% (EYBELIS®) is a selective prostaglandin E2 receptor subtype 2 (EP2) agonist with a unique non-prostaglandin chemical structure. It has been developed for the treatment of glaucoma and ocular hypertension, conditions characterized by elevated intraocular pressure that can lead to progressive optic nerve damage and vision loss if left untreated. The product is the result of a collaborative development effort between Ube Industries and Santen Pharmaceutical.

Unlike conventional prostaglandin analogs, omidenepag isopropyl acts selectively on the EP2 receptor, promoting increased aqueous humor outflow through both trabecular and uveoscleral pathways. This distinct mechanism of action offers effective intraocular pressure reduction while providing a differentiated therapeutic profile. Omidenepag isopropyl is administered as a once-daily ophthalmic solution, supporting patient compliance in long-term glaucoma management.

Based on positive outcomes from phase III clinical trials demonstrating its efficacy and safety, omidenepag isopropyl ophthalmic solution 0.002% received regulatory approval in Japan in September 2018. This approval marked the first global authorization for this novel EP2 receptor agonist in glaucoma and ocular hypertension treatment, representing an important advancement in ophthalmic therapeutic options.